| Heritage Pharmacueticals Inc. D/B/A Avet Pharmacueticals Inc |
23155064941 |
Carmustine for Injection |
2020-02-26 |
2637.3900 |
None |
1 |
466000 |
None |
None |
2012-11-28 |
None |
1 |
None |
Estimated Number of Patients is based on information obtained from Cancer.org and represents total patients diagnosed with cancers that could be treated by this product |
None |
| Hikma Pharmaceuticals USA Inc |
00054047121 |
Everolimus Tabs 0.5 mg, 60 |
2020-03-10 |
951.4300 |
These drugs are generic products; therefore no marketing and pricing plans are available. These products are sold in the United States only. |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma has not evaluated the volume of patients in the USA, as of January 2020 MAT IQVIA states a unit market size of 176,25. Hikma did not acquire this product. |
None |
| Hikma Pharmaceuticals USA Inc |
00054047221 |
Everolimus Tabs 0.75 mg, 60 |
2020-03-10 |
1427.1300 |
These drugs are generic products; therefore no marketing and pricing plans are available. These products are sold in the United States only. |
None |
None |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma has not evaluated the volume of patients in the USA, as of January 2020 MAT IQVIA states a unit market size of 176,25. Hikma did not acquire this product. |
None |
| Hikma Pharmaceuticals USA Inc |
00143963410 |
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection 20mg/200mL |
2020-04-22 |
1016.5000 |
These drugs are generic products; therefore no marketing and pricing plans are available. These products are sold in the United States only. |
None |
None |
None |
None |
2011-04-13 |
None |
1 |
None |
Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma has not evaluated the volume of patients in the USA. According to CDC.gov, the estimated number of patients with hypertension is 108,000,000.
The Nicardipine products referenced herein were transferred from Exela to Hikma in connection with a License Development, Supply, and Marketing Agreement executed on April 13, 2011. This agreement is not in the public domain and thus the acquisition price cannot be disclosed. |
None |
| Hikma Pharmaceuticals USA Inc |
00143963310 |
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection 40mg/200mL |
2020-04-22 |
2033.0000 |
These drugs are generic products; therefore no marketing and pricing plans are available. These products are sold in the United States only. |
None |
None |
None |
None |
2011-04-13 |
None |
1 |
None |
Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma has not evaluated the volume of patients in the USA. According to CDC.gov, the estimated number of patients with hypertension is 108,000,000.
The Nicardipine products referenced herein were transferred from Exela to Hikma in connection with a License Development, Supply, and Marketing Agreement executed on April 13, 2011. This agreement is not in the public domain and thus the acquisition price cannot be disclosed. |
None |
| Hikma Pharmaceuticals USA Inc |
00054048014 |
Everolimus Tablets 2.5mg, Blister Pack of 28 |
2020-06-08 |
12012.9800 |
These drugs are generic products; therefore no marketing and pricing plans are available. These products are sold in the United States only. |
None |
73750 |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. Hikma has not evaluated the volume of patients in the USA. Everolimus is a kinase inhibitor indicated for the treatment of (1) advanced renal cell carcinoma; and (2) renal angiomyolipoma and tuberous sclerosis complex. According to the American Cancer Society, in 2020 approximately 73,750 people will be diagnosed with advanced renal cell carcinoma. |
None |
| Hikma Pharmaceuticals USA Inc |
00054048114 |
Everolimus Tablets 5mg, Blister Pack of 28 |
2020-06-08 |
12565.3700 |
These drugs are generic products; therefore no marketing and pricing plans are available. These products are sold in the United States only. |
None |
73750 |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. Hikma has not evaluated the volume of patients in the USA. Everolimus is a kinase inhibitor indicated for the treatment of (1) advanced renal cell carcinoma; and (2) renal angiomyolipoma and tuberous sclerosis complex. According to the American Cancer Society, in 2020 approximately 73,750 people will be diagnosed with advanced renal cell carcinoma. |
None |
| Hikma Pharmaceuticals USA Inc |
00054049714 |
Everolimus Tablets 7.5mg, Blister Pack of 28 |
2020-06-08 |
12565.3700 |
These drugs are generic products; therefore no marketing and pricing plans are available. These products are sold in the United States only. |
None |
73750 |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. Hikma has not evaluated the volume of patients in the USA. Everolimus is a kinase inhibitor indicated for the treatment of (1) advanced renal cell carcinoma; and (2) renal angiomyolipoma and tuberous sclerosis complex. According to the American Cancer Society, in 2020 approximately 73,750 people will be diagnosed with advanced renal cell carcinoma. |
None |
| Hikma Pharmaceuticals USA Inc |
00054070219 |
Vigabatrin Oral Solution 500mg |
2020-09-25 |
1337.0600 |
This drug is a generic product; therefore no marketing and pricing plans are available. This product is sold in the United States only. |
None |
3400000 |
None |
None |
None |
None |
None |
None |
Hikma has not evaluated the volume of patients in the USA. Vigabatrin Oral Solution is indicated as adjunctive therapy for adults and pediatric patients 2 years of age and older with refractory complex partial seizures. According to CDC.gov, there are approximately 3.4 million people including children with epilepsy or seizure disorders nationwide. Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product. |
None |
| Hikma Pharmaceuticals USA Inc |
00054052863 |
Rufinamide Oral Solution 40mg/mL, bottle of 460mL |
2020-11-01 |
1540.3700 |
None |
1 |
86060 |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Hikma has not evaluated the volume of patients in the USA. Rufinamide Oral Solution is indicated as adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome ("LGS") in pediatric patients 1 year of age and older and in adults. The incidence of LGS is estimated at approximately 26 per 100,000 people. Therefore, there are approximately 86,060 patients in the United States. |
None |
| Hikma Pharmaceuticals USA Inc |
00054039925 |
Bexarotene Capsules 75mg |
2020-11-25 |
5885.0000 |
This drug is a generic product; therefore no marketing and pricing plans are available. This product is sold in the United States only. |
None |
77240 |
None |
None |
None |
None |
None |
None |
Pursuant to CA Health & Safety Code §127681 (c), Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Hikma has not evaluated the volume of patients in the USA. Bexarotene capsules are a retinoid indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. The American Cancer Society estimates that approximately 77,240 people will be diagnosed with T-cell lymphoma. |
None |
| Horizon Therapeutics USA, Inc. |
75987013015 |
Tepezza Intravenous Solution Reconstituted 500 MG, Single-Dose Vial |
2020-02-03 |
14900.0000 |
TEPEZZA is the first and only FDA-approved medicine for the treatment of Thyroid Eye Disease (TED), a serious, progressive and vision-threatening rare autoimmune disease that is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain, inflammation and facial disfigurement. Horizon's approach will focus on educating physicians about the disease state and TEPEZZA, providing education and support that simplifies the patient journey, and helping to facilitate access to TEPEZZA. TEPEZZA is a targeted biologic that addresses the underlying disease process, and its potential to significantly change the lives of people living with this rare and vision-threatening disease underscores the compelling value it offers. In addition to the value TEPEZZA brings to patients who previously had no meaningful options other than multiple eye surgeries, the pricing decision also reflects the significant investment made to develop and make an approved treatment available to a rare disease patient population. Horizon engaged in meaningful conversations with payors, as well as key members of the Thyroid Eye Disease community regarding this value in relation to pricing. |
None |
15000 |
1 |
1 |
None |
None |
None |
None |
None |
None |
| Horizon Therapeutics USA, Inc. |
75987014514 |
PROCYSBI (cysteamine bitartrate) delayed-release oral granules 300 MG, 120 Packets |
2020-04-23 |
48633.6000 |
The PROCYSBI Delayed-Release Oral Granules in Packets product provides another administration option for patients, in addition to PROCYSBI capsules. The new tear-open packets offer a convenient option for cystinosis patients who may have difficulty swallowing, need to sprinkle the granules on certain foods or mix with select liquids, or administer medication through a gastrostomy tube (G-tube). Additionally, the ability to access PROCYSBI granules in tear-open packets may help reduce the burden families living with cystinosis often face with managing multiple medications every day. Price remains consistent between 75mg capsules and 75mg and 300mg packets at the mg level. Horizon’s approach will continue to focus on educating physicians about the disease state and PROCYSBI, providing education and support that simplifies the patient journey, and helping to facilitate access to PROCYSBI. |
None |
15 |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank as Horizon did not acquire PROCYSBI Delayed-Release Oral Granules in Packets. Horizon expects there to be 60 patients on treatment this year across all four NDC’s, which is approximately 15 patients per NDC. MediSpan is showing market availability of 3/17/2020 as PROCYSBI was added to MediSpan earlier than the product was available for ordering. Actual market availability was 4/23/2020 as reflected in this report. |
None |
| Horizon Therapeutics USA, Inc. |
75987014513 |
PROCYSBI (cysteamine bitartrate) delayed-release oral granules 300 MG, 60 Packets |
2020-04-23 |
24316.8000 |
The PROCYSBI Delayed-Release Oral Granules in Packets product provides another administration option for patients, in addition to PROCYSBI capsules. The new tear-open packets offer a convenient option for cystinosis patients who may have difficulty swallowing, need to sprinkle the granules on certain foods or mix with select liquids, or administer medication through a gastrostomy tube (G-tube). Additionally, the ability to access PROCYSBI granules in tear-open packets may help reduce the burden families living with cystinosis often face with managing multiple medications every day. Price remains consistent between 75mg capsules and 75mg and 300mg packets at the mg level. Horizon’s approach will continue to focus on educating physicians about the disease state and PROCYSBI, providing education and support that simplifies the patient journey, and helping to facilitate access to PROCYSBI. |
None |
15 |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank as Horizon did not acquire PROCYSBI Delayed-Release Oral Granules in Packets. Horizon expects there to be 60 patients on treatment this year across all four NDC’s, which is approximately 15 patients per NDC. MediSpan is showing market availability of 3/17/2020 as PROCYSBI was added to MediSpan earlier than the product was available for ordering. Actual market availability was 4/23/2020 as reflected in this report. |
None |
| Horizon Therapeutics USA, Inc. |
75987014014 |
PROCYSBI (cysteamine bitartrate) delayed-release oral granules 75 MG, 120 Packets |
2020-04-23 |
12158.4000 |
The PROCYSBI Delayed-Release Oral Granules in Packets product provides another administration option for patients, in addition to PROCYSBI capsules. The new tear-open packets offer a convenient option for cystinosis patients who may have difficulty swallowing, need to sprinkle the granules on certain foods or mix with select liquids, or administer medication through a gastrostomy tube (G-tube). Additionally, the ability to access PROCYSBI granules in tear-open packets may help reduce the burden families living with cystinosis often face with managing multiple medications every day. Price remains consistent between 75mg capsules and 75mg and 300mg packets at the mg level. Horizon’s approach will continue to focus on educating physicians about the disease state and PROCYSBI, providing education and support that simplifies the patient journey, and helping to facilitate access to PROCYSBI. |
None |
15 |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank as Horizon did not acquire PROCYSBI Delayed-Release Oral Granules in Packets. Horizon expects there to be 60 patients on treatment this year across all four NDC’s, which is approximately 15 patients per NDC. MediSpan is showing market availability of 3/17/2020 as PROCYSBI was added to MediSpan earlier than the product was available for ordering. Actual market availability was 4/23/2020 as reflected in this report. |
None |
| Horizon Therapeutics USA, Inc. |
75987014013 |
PROCYSBI (cysteamine bitartrate) delayed-release oral granules 75 MG, 60 Packets |
2020-04-23 |
6079.2000 |
The PROCYSBI Delayed-Release Oral Granules in Packets product provides another administration option for patients, in addition to PROCYSBI capsules. The new tear-open packets offer a convenient option for cystinosis patients who may have difficulty swallowing, need to sprinkle the granules on certain foods or mix with select liquids, or administer medication through a gastrostomy tube (G-tube). Additionally, the ability to access PROCYSBI granules in tear-open packets may help reduce the burden families living with cystinosis often face with managing multiple medications every day. Price remains consistent between 75mg capsules and 75mg and 300mg packets at the mg level. Horizon’s approach will continue to focus on educating physicians about the disease state and PROCYSBI, providing education and support that simplifies the patient journey, and helping to facilitate access to PROCYSBI. |
None |
15 |
None |
None |
None |
None |
None |
None |
Acquisition fields left blank as Horizon did not acquire PROCYSBI Delayed-Release Oral Granules in Packets. Horizon expects there to be 60 patients on treatment this year across all four NDC’s, which is approximately 15 patients per NDC. MediSpan is showing market availability of 3/17/2020 as PROCYSBI was added to MediSpan earlier than the product was available for ordering. Actual market availability was 4/23/2020 as reflected in this report. |
None |